Literature DB >> 10774880

In vivo imaging of herpes simplex virus type 1 thymidine kinase gene expression: early kinetics of radiolabelled FIAU.

R Haubner1, N Avril, P A Hantzopoulos, B Gansbacher, M Schwaiger.   

Abstract

Previous studies have shown that the herpes simplex virus type 1 thymidine kinase gene (HSV1-tk), in combination with appropriate radiolabelled substrates (e.g. [I*]-2'-fluoro-2'-deoxy-5-iodo-1-beta-D-arabinofuranosyluracil, I*-FIAU, where the asterisk indicates that any of the various radioactive iodine isotopes can be used), can be used as a reporter gene for in vivo monitoring of gene transfer and expression. The aim of our study was to examine the early kinetics of I*-FIAU and the possibility of utilising iodine-123-labelled FIAU for imaging of gene expression. CMS-5 fibrosarcoma cells were transduced in vitro with the retroviral vector STK containing the HSV1-tk gene. BALB/c mice were inoculated subcutaneously with HSV1-tk(+) and tk(-) cells into both flanks. FAU (2'-fluoro-2'-deoxy-1-beta-D-arabinofuranosyluracil was radioiodinated (123I, 125I) using the iodogen method. High-performance liquid chromatography purification resulted in high specific activity and radiochemical purity for both tracers ([123I]FIAU and [125I]FIAU). Biodistribution studies and gamma camera imaging were performed at 0.5, 1, 2 and 4 h p.i. In addition, the genomic DNA of the tumours was isolated for measurement of the activity accumulation resulting from the [125I]FIAU incorporation. Biodistribution studies 0.5 h p.i. showed tumour/blood and tumour/muscle ratios of 3.8 and 7.2, respectively, for the HSV1-tk(+) tumours, and 0.6 and 1.2, respectively, for negative control tumours. Fast renal elimination of the tracer from the body resulted in rapidly increasing tumour/blood and tumour/muscle ratios which reached values of 32 and 88 at 4 h p.i., respectively. Tracer clearance from blood was bi-exponential, with an initial half-life of 0.6 h followed by a half-life of 4.6 h. The tracer half-life in herpes simplex viral thymidine kinase-expressing tumours was 35.7 h. The highest activity accumulation (20.3%+/-5.7% ID/g) in HSV1-tk(+) tumours was observed 1 h p.i. At that time, about 46% of the total activity found in HSV1-tk(+) tumours was incorporated into genomic DNA. Planar gamma camera imaging showed a distinct tracer accumulation as early as 0.5 h p.i., with an increase in contrast over time. These results suggest that sufficient tumour/background ratios for in vivo imaging of HSV1-tk expression with [123I]FIAU are reached as early as 1 h p.i.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10774880     DOI: 10.1007/s002590050035

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  12 in total

Review 1.  Defining the success of cardiac gene therapy: how can nuclear imaging contribute?

Authors:  Norbert Avril; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-23       Impact factor: 9.236

2.  Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo.

Authors:  V Ponomarev; M Doubrovin; C Lyddane; T Beresten; J Balatoni; W Bornman; R Finn; T Akhurst; S Larson; R Blasberg; M Sadelain; J G Tjuvajev
Journal:  Neoplasia       Date:  2001 Nov-Dec       Impact factor: 5.715

3.  Non-invasive in vivo imaging with radiolabelled FIAU for monitoring cancer gene therapy using herpes simplex virus type 1 thymidine kinase and ganciclovir.

Authors:  Win-Ping Deng; Wen K Yang; Wen-Fu Lai; Ren-Shyan Liu; Jeng-Jong Hwang; Den-Mei Yang; Ying-Kai Fu; Hsin-Ell Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-25       Impact factor: 9.236

Review 4.  Imaging virus-associated cancer.

Authors:  De-Xue Fu; Catherine A Foss; Sridhar Nimmagadda; Richard F Ambinder; Martin G Pomper
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

5.  Human breast tumor cells express multimodal imaging reporter genes.

Authors:  Kurt M Lin; Ching-Han Hsu; Wun-Shaing W Chang; Chiung-Tong Chen; Te-Wei Lee; Chin-Tu Chen
Journal:  Mol Imaging Biol       Date:  2008-06-17       Impact factor: 3.488

6.  Comparison of cell-labeling methods with ¹²⁴I-FIAU and ⁶⁴Cu-PTSM for cell tracking using chronic myelogenous leukemia cells expressing HSV1-tk and firefly luciferase.

Authors:  Jae-Jun Park; Tae-Sup Lee; Jin-Ju Son; Kwon-Soo Chun; In-Ho Song; Yong-Serk Park; Kwang-Il Kim; Yong-Jin Lee; Joo-Hyun Kang
Journal:  Cancer Biother Radiopharm       Date:  2012-09-25       Impact factor: 3.099

Review 7.  PET-based molecular imaging in neuroscience.

Authors:  A H Jacobs; H Li; A Winkeler; R Hilker; C Knoess; A Rüger; N Galldiks; B Schaller; J Sobesky; L Kracht; P Monfared; M Klein; S Vollmar; B Bauer; R Wagner; R Graf; K Wienhard; K Herholz; W D Heiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-23       Impact factor: 9.236

8.  Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors.

Authors:  De-Xue Fu; Yvette Tanhehco; Jianmeng Chen; Catherine A Foss; James J Fox; Ja-Mun Chong; Robert F Hobbs; Masashi Fukayama; George Sgouros; Jeanne Kowalski; Martin G Pomper; Richard F Ambinder
Journal:  Nat Med       Date:  2008-09-07       Impact factor: 53.440

9.  In Vivo Noninvasive Imaging for Gene Therapy.

Authors:  Georges Vassaux; Thomas Groot-Wassink
Journal:  J Biomed Biotechnol       Date:  2003

10.  Remnant living cells that escape cell loss in late-stage tumors exhibit cancer stem cell-like characteristics.

Authors:  Y L Chen; S Y Wang; R S Liu; H E Wang; J C Chen; S H Chiou; C A Chang; L T Lin; D T W Tan; Y J Lee
Journal:  Cell Death Dis       Date:  2012-10-04       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.